Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Open access
Fan, Rong, Papatheodoridis, George, Sun, Jian, Innes, Hamish, Toyoda, Hidenori, Xie, Qing, Mo, Shuyuan, Sypsa, Vana, Guha, Indra Neil, Kumada, Takashi, Niu, Junqi, Dalekos, George, Yasuda, Satoshi, Barnes, Eleanor, Lian, Jianqi, Suri, Vithika, Idilman, Ramazan, Barclay, Stephen T., Dou, Xiaoguang, Berg, Thomas, Hayes, Peter C., Flaherty, John F., Zhou, Yuanping, Zhang, Zhengang, Buti, Maria, Hutchinson, Sharon J., Guo, Yabing, Calleja, Jose Luis, Lin, Lanjia, Zhao, Longfeng, Chen, Yongpeng, Janssen, Harry L.A., Zhu, Chaonan, Shi, Lei, Tang, Xiaoping, Gaggar, Anuj, Wei, Lai, Jia, Jidong, Irving, William L., Johnson, Philip J., Lampertico, Pietro, Hou, Jinlin·2020·Journal of Hepatology

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis. METHODS: A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686). RESULTS: We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%. CONCLUSIONS: This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide. LAY SUMMARY: In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2020.07.025

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 364

Metadata

Authors
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., Niu, J., Dalekos, G., Yasuda, S., Barnes, E., Lian, J., Suri, V., Idilman, R., Barclay, S. T., Dou, X., Berg, T., Hayes, P. C., Flaherty, J. F., Zhou, Y., Zhang, Z., Buti, M., Hutchinson, S. J., Guo, Y., Calleja, J. L., Lin, L., Zhao, L., Chen, Y., Janssen, H. L. A., Zhu, C., Shi, L., Tang, X., Gaggar, A., Wei, L., Jia, J., Irving, W. L., Johnson, P. J., Lampertico, P., & Hou, J.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-12
Volume
73
Issue
6
Pages
1368-1378
ISSN
0168-8278 (ISSN-L)
OpenAlex
W3044553904
Cited by
364
References
21
FWCI
19.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.07.025
The paper
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., Niu, J., Dalekos, G., Yasuda, S., Barnes, E., Lian, J., Suri, V., Idilman, R., Barclay, S. T., Dou, X., . . . Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.07.025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.